Drug Channels

MARCH 28, 2024

Bill discusses specialty therapy access barriers, including payer utilization management techniques and “no coverage” policies. Today’s guest post comes from Bill Dupere, SVP of Product Development & Partnerships at Mercalis. Contact Mercalis to learn about their Patient Support Services. Read on for Bill’s insights.

Marketing 98

Marketing Science Therapies Production 98

ASPET

OCTOBER 20, 2023

However, Pramlintide an adjunct to insulin therapy, enhances glucagon suppression and thereby offers improved glycaemic control. Although clinical benefits of Pramlintide are well reported, there still exists a high patient resistance for the therapy as separate injections for Pramlintide and insulin are required to be administered.

Therapies 100

Therapies Pharmacokinetics Treatment Marketing 100

PPD

OCTOBER 17, 2024

Cell and gene therapy (CGT) studies are rapidly gaining momentum in the Asia-Pacific region, fueled by growing patient demand and a thriving ecosystem of innovation. In China, the high incidence of solid tumors is driving an urgent need for advanced therapies, spurring the push for new treatment approaches.

Therapies 79

Therapies Clinical Trials Clinical Research Trials 79

Drug Target Review

JUNE 19, 2024

The mission of Lineage Cell Therapeutics is to deliver on some of the early promises of cell therapy. Cell therapy as a concept is a wonderful idea, but many of the early efforts never generated the kind of clinical data that gets people excited and leads to new medicines. In some cases, cell therapy can be curative for the patient.

Therapies 84

Therapies Small Molecule Pharmaceutical Companies Molecular Biology 84

Fierce BioTech

SEPTEMBER 24, 2024

Unlocking European market access for rare disease therapies The European orphan drug market presents a significant opportunity for biotech firms. Learn more about early access programs (EAPs), and how they are emerging as a critical strategy for successfully launching rare disease therapies in this complex and diverse market.

Marketing 40

Marketing Therapies Disease Drugs 40

Fierce BioTech

MARCH 15, 2024

Oncology Market Outlook 2024 This paper assesses the current state of the oncology market, reviewing key expectations for 2024. It addresses CAR-T therapies, KRAS, radiopharmaceuticals, & targeted protein degradation. It addresses CAR-T therapies, KRAS, radiopharmaceuticals, & targeted protein degradation.

Targeted Protein Degradation 52

Targeted Protein Degradation Marketing Therapies Science 52

BioPharma Drive: Drug Pricing

DECEMBER 6, 2023

The funds are meant to boost Fujifilm’s capacity to manufacture cell therapies, a market it expects to grow substantially in the coming years.

Therapies 70

Therapies Production Marketing 70

BioPharma Drive: Drug Pricing

MAY 13, 2024

Goldman Sachs and Eli Lilly are among those backing the startup, which claims its prospect could be more potent than the myelofibrosis therapies that have come to market in recent years.

Therapies 131

Therapies Marketing Drugs 131

Conversations in Drug Development Trends

NOVEMBER 12, 2024

By Amy Raymond, PhD, PMP, Executive Director, Therapeutic Strategy Lead, Rare Disease Cell and gene therapies (CGTs) include cutting-edge approaches that offer the hope of a healthier, happier, and better tomorrow for a wide range of patient populations. Below, we discuss some of these challenges in cell therapy trials.

Therapies 72

Therapies Clinical Supply Clinical Trials Molecular Biology 72

BioPharma Drive: Drug Pricing

JULY 3, 2024

Multibillion-dollar buyouts from Bristol Myers Squibb and Gilead could yield new drugs for brain and liver diseases, while a new cell therapy may reach market.

FDA 127

FDA Therapies Disease Marketing 127

Drug Target Review

FEBRUARY 21, 2024

Stem cell transplants have saved patients’ lives time and time again, which led us to launch our own Stem Cell Transplant and Cellular Therapy Program. Regarding CAR-T cell therapy, could you highlight the promising findings that have been identified in the early stages of drug discovery, as well as potential challenges?

Therapies 64

Therapies Treatment Vaccine FDA Approval 64

LifeSciVC

NOVEMBER 28, 2023

Market conditions like this are demoralizing in the worst way. Furthermore, to make matters even more complicated, that same summer, markets had already turned sour, and the sentiment was darkening by the day. The biotech equity markets had effectively shut off the idea of an IPO (which was one of several paths we had mapped out).

Marketing 84

Marketing FDA Pharma Companies Government 84

Drug Target Review

AUGUST 6, 2024

Liver Fibrosis : Targeted therapies using ADCs could help reduce liver fibrosis and prevent the progression to cirrhosis. Expedited programs like the FDA’s Breakthrough Therapy Designation and Fast Track can shorten development timelines and reduce risk. Oncology drugs often command high prices, potentially leading to higher ROI.

Therapies 119

Therapies Pharmaceutical Companies Disease Treatment 119

Drug Target Review

SEPTEMBER 6, 2024

What trends are driving the increased use of in vivo delivery methods in gene therapy? How is the market demand for lentiviral vectors evolving, and what factors are influencing this growth? There is a very significant increased market demand for lentiviral vectors. New therapeutic areas are emerging in a powerful way.

Therapies 59

Therapies Vaccine Marketing Disease 59

ASPET

OCTOBER 12, 2023

The CET RAIDR program conserves both time-to-market and funds by leveraging previous conventional development work as a launch point for repurposing efforts. CBRN MCMs).

Therapies 100

Therapies Licensing Licensing FDA Approval 100

BioPharma Drive: Drug Pricing

MARCH 20, 2024

million list price, the highest of any genetic medicine to come to market. Orchard is counting on the long-term data it’s accrued to convince insurers to cover Lenmeldy’s $4.25

Therapies 82

Therapies Marketing 82

Antidote

APRIL 4, 2024

Before it is released onto the market, the development of any new drug or medical device must undergo rigorous testing , part of which involves clinical trials. Clinical trials are integral to making sure that any new therapy is both safe and effective for individuals, and volunteers are a vital part of the process.

Clinical Trials 119

Clinical Trials Trials Therapies Marketing 119

ASPET

SEPTEMBER 7, 2023

Avalglucosidase alfa has received marketing authorization in several countries for infantile-onset and/or late-onset Pompe disease. This recently approved enzyme replacement therapy (ERT) was glycoengineered to maximize CIMPR binding through high-affinity interactions with ~7 bis-M6P moieties.

Small Molecule 100

Small Molecule Therapies Disease Treatment 100

Fierce BioTech

JUNE 13, 2024

Discover how this innovative digital design system is helping increase patient medication adherence and the length of therapies, by moving beyond segmentation to truly personalized experiences. Listing Image AllazoHealth_ListingLogo_250x190.png On Demand Start Date Wed, 08/07/2024 - 12:00

Marketing 52

Marketing Therapies 52

BioPharma Drive: Drug Pricing

OCTOBER 10, 2024

Data readouts over the next six months could set expectations for how the highly lucrative market for weight loss therapies will look in the future.

Trials 109

Trials Therapies Marketing 109

Fierce BioTech

JULY 17, 2024

Accelerate your cell therapy to clinic with a flexible CGMP-ready process The cell therapy market holds great promise, yet faces challenges like material variability and the need for standardization. Download this whitepaper to discover how to de-risk these challenges and meet the evolving needs of the cell therapy market.

Therapies 52

Therapies Marketing 52

PLOS: DNA Science

OCTOBER 12, 2023

In the final chapter of my 2012 book The Forever Fix: Gene Therapy and the Boy Who Saved It , I predicted that the technology would soon expand well beyond the rare disease world. Gene therapy clearly hasn’t had a major impact on health care, offering extremely expensive treatments for a few individuals with rare diseases.

Therapies 69

Therapies Immune Response DNA Virus 69

Drug Patent Watch

JANUARY 13, 2025

As we delve into the intricate world of biosimilar market dynamics, we’ll explore how these complex molecules are reshaping treatment paradigms across diverse patient populations. ”[1] The global biosimilars market is experiencing exponential growth, with projections indicating it will reach $69.4 from 2020 to 2025[1].

Biosimilars 52

Biosimilars Marketing Treatment Small Molecule 52

Agency IQ

NOVEMBER 3, 2023

Probiotics, a type of microbiome-based therapy containing live micro-organisms, are broadly available on drug store and grocery store shelves, but the regulatory classifications for products containing the same micro-organism can differ dramatically. Fill out the form to read the full article.

Therapies 59

Therapies Production Marketing Drugs 59

Drug Channels

MAY 9, 2023

Last week, Paula and I had the pleasure of attending Asembia’s 2023 Specialty Pharmacy Summit at the wonderful Wynn Las Vegas. As I do every year, I will violate Vegas code and tell you what happened there.

Specialty Pharmacies 98

Specialty Pharmacies Marketing Pharmacy Drugs 98

Drug Target Review

JULY 4, 2023

These therapies have broadened treatment options for patients to expand beyond the more traditional small molecule drug alternatives. The global ADC market is expected to continue this steep upward trajectory and is anticipated to exceed $16 Billion by 2026. 3D rendering of Antibody Drug Conjugate Molecules.

Small Molecule 145

Small Molecule Drugs Clinical Pharmacology Trials 145

Fierce BioTech

JANUARY 16, 2025

Yet the process of getting to market and enabling patient access is far from simple. The complex clinical planning, potential for nuanced regulatory hurdles, payer scrutiny, and supply chain complexity all necessitate early and strategic planning to optimize patient access to these novel treatment options at launch.

Therapies 52

Therapies Treatment Disease Marketing 52

Drug Target Review

DECEMBER 5, 2024

Viral vectors have been crucial in transforming the gene therapy landscape due to their natural ability to infect cells. 1 In 2017, the US Food and Drug Administration (FDA) approved the first AAV-based gene replacement therapy (Luxturna), for Leber congenital amaurosis type 2.

Therapies 52

Therapies Virus DNA Compliance 52

Drug Target Review

AUGUST 29, 2024

What potential advantages does the CD5 modulation strategy offer over traditional CAR-T therapies? MR : Chimeric antigen receptor T-cell (CAR-T) therapy is very effective in treating patients with B-cell lymphoma, leukemia, and multiple myeloma, where we have six FDA-approved drugs.

Therapies 59

Therapies Treatment Engineering Molecular Biology 59

DS in Pharmatics

JUNE 10, 2023

On April 12, 2023, BeNeLuxA1 announced that negotiations failed to secure reimbursement for Libmeldy, a gene therapy developed by Orchard Therapeutics for the treatment of metachromatic leukodystrophy, on grounds of price. In the UK, an initial application to NICE was rejected as well back in 2020. This is a huge […]

Marketing 66

Marketing Therapies Treatment 66

Fierce BioTech

OCTOBER 5, 2023

Discover Strategies for Combatting Disruptions in Gene Therapy Development Cell and gene therapy development has exploded, with Q4 2022 showing more FDA approvals than over the past five years combined.[1] 1] How can sponsors keep pace with this rapidly growing market and avoid costly delays that can threaten critical timelines?

Therapies 52

Therapies FDA Approval FDA Marketing 52

Antidote

JULY 27, 2023

Before any new therapy can be put on the market, it must be tested to ensure its safety and effectiveness, and the research for this process is done through clinical trials.

Clinical Research 98

Clinical Research Research Clinical Trials Packaging 98

Advarra

JUNE 13, 2023

Research in gene therapies and genetically engineered drugs and vaccines are growing exponentially, and will only continue to become more popular. The accelerating gene therapy market is expected to grow globally by 16.6% As more therapies are moving out of the lab and into human clinical trials, this paradigm is changing.

Therapies 52

Therapies Research Clinical Trials Trials 52

Quanticate

NOVEMBER 21, 2024

They are essential for assessing whether new cancer therapies are safe and efficacious [1]. This can speed up the market approval of new agents with the potential to save or extend lives [2]. Endpoints may serve different purposes, from evaluating survival rates to monitoring tumour size, as well as monitoring patient symptoms.

Clinical Trials 98

Clinical Trials Trials Therapies Treatment 98

Advarra

JANUARY 11, 2024

The applications of mRNA-based therapies in cancer research represent one of the next groundbreaking steps toward improved cancer treatments. Adoptive T Cell therapies, therapeutic antibodies, and immunomodulatory proteins represent just some of the potentially beneficial treatment strategies for successful mRNA cancer trials.

Vaccine 52

Vaccine Therapies Clinical Trials Small Molecule 52

BioPharma Drive: Drug Pricing

MAY 6, 2024

One analyst thinks the collaboration “bodes well” for Gossamer, which has had trouble convincing investors its drug seralutinib can compete on the market.

Therapies 70

Therapies Drugs Marketing 70

Antidote

JULY 29, 2022

The process of getting a new drug to market is an expensive one. billion to bring a new therapy to market. Between 2009 and 2018, U.S. biopharmaceutical companies spent about $1 billion per drug according to an analysis published in JAMA , and other studies have found that it can cost up to $2.8

Clinical Trials 96

Clinical Trials Trials Therapies Pharmaceuticals 96